FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1528823654> ?p ?o ?g. }

• W1528823654 endingPage "58" @default.
• W1528823654 startingPage "5649" @default.
• W1528823654 abstract "Preliminary reports have demonstrated that (99m)technetium (Tc)-labeled cyclic [Cys(3,4,10), D-Phe7]alpha-MSH(3-13) (CCMSH) exhibits high tumor uptake and retention values in a murine melanoma mouse model. In this report, the tumor targeting mechanism of 99mTc-CCMSH was studied and compared with four other radiolabeled alpha-melanocyte stimulating hormone (alpha-MSH) peptide analogues: 125I-(Tyr2)-[Nle4, D-Phe7]alpha-MSH [125I-(Tyr2)-NDP]; 99mTc-CGCG-NDP; 99mTc-Gly11-CCMSH; and 99mTc-Nle11-CCMSH. In vitro receptor binding, internalization, and cellular retention of radiolabeled alpha-MSH analogues in B16/F1 murine cell line demonstrated that >70% of the receptor-bound radiolabeled analogues were internalized together with the receptor. Ninety % of the internalized 125I-(Tyr2)-NDP, whereas only 36% of internalized 99mTc-CCMSH, was released from the cells into the medium during a 4-h incubation at 37 degrees C. Two mouse models, C57 mice and severe combined immunodeficient (Scid) mice, inoculated s.c. with B16/F1 murine and TXM-13 human melanoma cells were used for the in vivo studies. Tumor uptake values of 11.32 and 2.39 [% injected dose (ID)/g] for 99mTc-CCMSH at 4 h after injection, resulted in an uptake ratio of tumor:blood of 39.0 and 11.5 in murine melanoma-C57 and human melanoma-Scid mouse models, respectively. Two strategies for decreasing the nonspecific kidney uptake of 99mTc-CCMSH, substitution of Lys11 in CCMSH with Gly11 or Nle11, and lysine coinjection, were evaluated. The biodistribution data for the modified peptides showed that Lys11 replacement dramatically decreased the kidney uptake, whereas the tumor uptakes of 99mTc-Nle11- and 99mTc-Gly11-CCMSH were significantly lower than that of 99mTc-CCMSH. Lysine coinjection significantly decreased the kidney uptake (e.g., from 14.6% ID/g to 4.5% ID/g at 4 h after injection in murine melanoma-C57 mice) without significantly changing the value of tumor uptake of 99mTc-CCMSH. In conclusion, the compact cyclic structure of 99mTc-CCMSH, its resistance to degradation, and its enhanced intracellular retention are the major contributing factors to the superior in vivo tumor targeting properties of 99mTc-CCMSH. Lys11 residue in 99mTc-CCMSH is critical to the tumor targeting in vivo, and lysine coinjection rather than lysine replacement can significantly decrease the nonspecific renal radioactivity accumulation without impeding the high melanoma-targeting properties of 99Tc-CCMSH. The metal-cyclized CCMSH molecule displays excellent potential for the development of melanoma-specific diagnostic and therapeutic agents." @default.
• W1528823654 created "2016-06-24" @default.
• W1528823654 creator A5001152143 @default.
• W1528823654 creator A5014582607 @default.
• W1528823654 creator A5058337709 @default.
• W1528823654 creator A5075963891 @default.
• W1528823654 creator A5085131390 @default.
• W1528823654 date "2000-10-15" @default.
• W1528823654 modified "2023-09-25" @default.
• W1528823654 title "Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues." @default.
• W1528823654 cites W143550348 @default.
• W1528823654 cites W1605645272 @default.
• W1528823654 cites W1885075954 @default.
• W1528823654 cites W1970716955 @default.
• W1528823654 cites W1973069842 @default.
• W1528823654 cites W1978868436 @default.
• W1528823654 cites W1980604941 @default.
• W1528823654 cites W1995298955 @default.
• W1528823654 cites W1995319184 @default.
• W1528823654 cites W1996018952 @default.
• W1528823654 cites W2006108835 @default.
• W1528823654 cites W2015370922 @default.
• W1528823654 cites W2015546047 @default.
• W1528823654 cites W2020367089 @default.
• W1528823654 cites W2020612257 @default.
• W1528823654 cites W2024779106 @default.
• W1528823654 cites W2037494979 @default.
• W1528823654 cites W2039085331 @default.
• W1528823654 cites W2043997061 @default.
• W1528823654 cites W2047631015 @default.
• W1528823654 cites W2058245862 @default.
• W1528823654 cites W2058426435 @default.
• W1528823654 cites W2060947783 @default.
• W1528823654 cites W2062847609 @default.
• W1528823654 cites W2075144557 @default.
• W1528823654 cites W2084838114 @default.
• W1528823654 cites W2091939318 @default.
• W1528823654 cites W2099564842 @default.
• W1528823654 cites W2100669107 @default.
• W1528823654 cites W2101395524 @default.
• W1528823654 cites W2104096550 @default.
• W1528823654 cites W2109687538 @default.
• W1528823654 cites W2143714687 @default.
• W1528823654 cites W2417679862 @default.
• W1528823654 cites W2434885040 @default.
• W1528823654 cites W2466398933 @default.
• W1528823654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11059756" @default.
• W1528823654 hasPublicationYear "2000" @default.
• W1528823654 type Work @default.
• W1528823654 sameAs 1528823654 @default.
• W1528823654 citedByCount "39" @default.
• W1528823654 countsByYear W15288236542012 @default.
• W1528823654 countsByYear W15288236542014 @default.
• W1528823654 countsByYear W15288236542015 @default.
• W1528823654 countsByYear W15288236542016 @default.
• W1528823654 countsByYear W15288236542017 @default.
• W1528823654 countsByYear W15288236542018 @default.
• W1528823654 countsByYear W15288236542019 @default.
• W1528823654 countsByYear W15288236542022 @default.
• W1528823654 crossrefType "journal-article" @default.
• W1528823654 hasAuthorship W1528823654A5001152143 @default.
• W1528823654 hasAuthorship W1528823654A5014582607 @default.
• W1528823654 hasAuthorship W1528823654A5058337709 @default.
• W1528823654 hasAuthorship W1528823654A5075963891 @default.
• W1528823654 hasAuthorship W1528823654A5085131390 @default.
• W1528823654 hasConcept C126322002 @default.
• W1528823654 hasConcept C134018914 @default.
• W1528823654 hasConcept C13965031 @default.
• W1528823654 hasConcept C139770010 @default.
• W1528823654 hasConcept C150903083 @default.
• W1528823654 hasConcept C153911025 @default.
• W1528823654 hasConcept C170493617 @default.
• W1528823654 hasConcept C185592680 @default.
• W1528823654 hasConcept C202751555 @default.
• W1528823654 hasConcept C207001950 @default.
• W1528823654 hasConcept C2777658100 @default.
• W1528823654 hasConcept C2777807558 @default.
• W1528823654 hasConcept C2779281246 @default.
• W1528823654 hasConcept C2779769559 @default.
• W1528823654 hasConcept C2780989459 @default.
• W1528823654 hasConcept C502942594 @default.
• W1528823654 hasConcept C522557706 @default.
• W1528823654 hasConcept C54355233 @default.
• W1528823654 hasConcept C55493867 @default.
• W1528823654 hasConcept C71924100 @default.
• W1528823654 hasConcept C81885089 @default.
• W1528823654 hasConcept C86803240 @default.
• W1528823654 hasConceptScore W1528823654C126322002 @default.
• W1528823654 hasConceptScore W1528823654C134018914 @default.
• W1528823654 hasConceptScore W1528823654C13965031 @default.
• W1528823654 hasConceptScore W1528823654C139770010 @default.
• W1528823654 hasConceptScore W1528823654C150903083 @default.
• W1528823654 hasConceptScore W1528823654C153911025 @default.
• W1528823654 hasConceptScore W1528823654C170493617 @default.
• W1528823654 hasConceptScore W1528823654C185592680 @default.
• W1528823654 hasConceptScore W1528823654C202751555 @default.
• W1528823654 hasConceptScore W1528823654C207001950 @default.
• W1528823654 hasConceptScore W1528823654C2777658100 @default.

• next